CordenPharma buys AmbioPharm

CordenPharma, has entered into an agreement to acquire AmbioPharm, a peptide API CDMO with sites in North Augusta, South Carolina, and Shanghai that employ about 400. Terms were not disclosed but it is known that AmbioPharm’s shareholders will reinvest into the combined business.

The company said that AmbioPharm will add differentiated peptide manufacturing capabilities to its existing platform of 11 sites in Europe and North America. This has already grown considerably since Astorg acquired CordenPharma in 2022.

“AmbioPharm’s capabilities perfectly complement our existing peptide expertise, helping us to broaden the ways we support customers from development to commercialisation,” claimed Dr Michael Quirmbach, president and CEO of CordenPharma.

The combined platform will include advanced linear and fragment-based peptide approaches supported by flexible solid- and liquid-phase peptide synthesis (SPPS/LPPS), hybrid synthesis and CordenPharma’s tag-assisted peptide synthesis (TAPS). The North Augusta plant will also add significant purification and lyophilisation capacity.